MX2022005547A - Derivados terapeuticos de interleucina-22. - Google Patents

Derivados terapeuticos de interleucina-22.

Info

Publication number
MX2022005547A
MX2022005547A MX2022005547A MX2022005547A MX2022005547A MX 2022005547 A MX2022005547 A MX 2022005547A MX 2022005547 A MX2022005547 A MX 2022005547A MX 2022005547 A MX2022005547 A MX 2022005547A MX 2022005547 A MX2022005547 A MX 2022005547A
Authority
MX
Mexico
Prior art keywords
interleukin
therapeutic derivatives
derivatives
therapeutic
therapy
Prior art date
Application number
MX2022005547A
Other languages
English (en)
Inventor
Henning Thøgersen
Kristian Sass-Ørum
Thomas Hoeg-Jensen
Rasmus Jørgensen
Sebastian Beck Jørgensen
Michael Paolo Bastner Sandrini
Original Assignee
Cytoki Pharma Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytoki Pharma Aps filed Critical Cytoki Pharma Aps
Publication of MX2022005547A publication Critical patent/MX2022005547A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La invención se refiere a nuevos derivados de interleucina-22 (IL-22), particularmente aquellos que comprenden un ácido graso unido de forma covalente a una proteína IL-22, y su uso en terapia.
MX2022005547A 2019-11-07 2020-11-09 Derivados terapeuticos de interleucina-22. MX2022005547A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19207766.7A EP3819307A1 (en) 2019-11-07 2019-11-07 Therapeutic derivatives of interleukin-22
PCT/EP2020/081523 WO2021089875A1 (en) 2019-11-07 2020-11-09 Therapeutic derivatives of interleukin-22

Publications (1)

Publication Number Publication Date
MX2022005547A true MX2022005547A (es) 2022-07-04

Family

ID=68502950

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005547A MX2022005547A (es) 2019-11-07 2020-11-09 Derivados terapeuticos de interleucina-22.

Country Status (15)

Country Link
US (3) US11806403B2 (es)
EP (2) EP3819307A1 (es)
JP (2) JP2023502005A (es)
KR (1) KR20220097921A (es)
CN (1) CN114761422A (es)
AU (1) AU2020378648A1 (es)
BR (1) BR112022008497A2 (es)
CA (1) CA3160338A1 (es)
CL (1) CL2022001185A1 (es)
CO (1) CO2022005889A2 (es)
CR (1) CR20220249A (es)
IL (1) IL292657A (es)
MX (1) MX2022005547A (es)
PE (1) PE20221279A1 (es)
WO (1) WO2021089875A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3819307A1 (en) 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
WO2021207662A1 (en) * 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
KR20230004645A (ko) * 2020-04-17 2023-01-06 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 조작된 인터루킨-22 폴리펩타이드 및 이의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR106F (es) 1964-12-21
JP2013533227A (ja) 2010-06-08 2013-08-22 ノヴォ ノルディスク アー／エス Ｆｇｆ２１類似体および誘導体
KR102025442B1 (ko) 2010-12-22 2019-09-25 박스알타 인코퍼레이티드 단백질에 수용성 지방산 유도체를 접합하기 위한 물질 및 방법
SI2970422T1 (en) 2013-03-15 2018-07-31 F. Hoffmann-La Roche Ag IL-22 polypeptides and IL-22-Fc fusion proteins and procedures for use
JP6822839B2 (ja) 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、及びその組成物
MA41794A (fr) 2015-03-18 2018-01-23 The California Institute For Biomedical Res Agents thérapeutiques modifiés et compositions associées
SG10201912066SA (en) * 2015-07-15 2020-02-27 Protagonist Therapeutics Inc Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP2020529976A (ja) * 2017-08-03 2020-10-15 シンソークス，インク． 自己免疫疾患の処置のためのサイトカイン抱合体
EP3819307A1 (en) 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22

Also Published As

Publication number Publication date
CA3160338A1 (en) 2021-05-14
US20230381320A1 (en) 2023-11-30
IL292657A (en) 2022-07-01
JP2023083380A (ja) 2023-06-15
CL2022001185A1 (es) 2023-02-03
US20240108731A1 (en) 2024-04-04
JP7479539B2 (ja) 2024-05-08
JP2023502005A (ja) 2023-01-20
BR112022008497A2 (pt) 2022-07-26
CO2022005889A2 (es) 2022-07-29
CN114761422A (zh) 2022-07-15
US20220347304A1 (en) 2022-11-03
EP3819307A1 (en) 2021-05-12
US11806403B2 (en) 2023-11-07
AU2020378648A1 (en) 2022-06-23
CR20220249A (es) 2022-08-19
EP4055035A1 (en) 2022-09-14
PE20221279A1 (es) 2022-09-05
WO2021089875A1 (en) 2021-05-14
KR20220097921A (ko) 2022-07-08

Similar Documents

Publication Publication Date Title
NZ761434A (en) Cytokine conjugates for the treatment of autoimmune diseases
CR20220249A (es) Derivados terapéuticos de interleucina-22
AU2022228122B2 (en) Interleukin-21 muteins and methods of treatment
MX2019011215A (es) Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
PH12020551261A1 (en) Il-15 conjugates and uses thereof
WO2018033254A3 (en) Rna for cancer therapy
PH12019502621A1 (en) Antibody-cytokine engrafted proteins and methods of use in the treatement of cancer
WO2019083990A3 (en) IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING FIBROBLAST-ACTIVATION PROTEIN-α (FAP-α)
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
MX2021015370A (es) Composiciones farmaceuticas de un inhibidor de tirosina cinasa de bruton.
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
MX2017011794A (es) Composiciones y metodos para diagnosticos y tratamiento del cancer.
MX2022002740A (es) Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
MX2020008208A (es) Agentes de unión a fibroblastos y uso de estos.
JOP20220071A1 (ar) سيتوكين مناعي يشمل معقد بروتين دايمري غير متجانس على أساس IL-15/IL-15Ra
AU201815816S (en) Inhaler
MX2022003758A (es) Composiciones para el cuidado bucal que comprenden acido beta de lupulo y aminoacido.
CY1125014T1 (el) Υποκατεστημενα παραγωγα ξανθινης
MX2018009499A (es) Anticuerpos monoclonales especificos de egfl6 y metodos de su uso.
WO2020180712A8 (en) Anti-tnfr2 antibodies and uses thereof
MX2021015333A (es) Combinaciones de inhibidores para el tratamiento de enfermedades relacionadas con la expresion de dux4.
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
MX2020010932A (es) Enzimas quinureninasa humanas y sus usos.
WO2019055776A3 (en) Compositions and methods for treatment of diseases involving cxcl1 function
MX2019002422A (es) Proteina sin fenilalanina para el tratamiento de pku.